Maravai LifeSciences Holdings Sees Fair Value Estimate Revised Downward, Analyst Sentiment Shifts.

Maravai LifeSciences Holdings' fair value estimate has been revised downward from $4.13 to $3.86, with a slight increase in its discount rate from 8.37% to 8.63%. Analyst sentiment has become more cautious following the latest quarterly results, with Stifel maintaining a Buy rating despite the recent underperformance. The firm sees upside potential for long-term investors and notes that the stock appears "fairly washed out" at current levels. However, the analyst lowered the price target to $4 from $5 and acknowledges "low visibility" amid ongoing leadership transitions. The outlook still leaves room for future upside should the new management team deliver improved results.